Caris Life Sciences Stock (NASDAQ:CAI)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$26.54

52W Range

$22.86 - $42.50

50D Avg

$28.26

200D Avg

$30.08

Market Cap

$7.55B

Avg Vol (3M)

$1.45M

Beta

-

Div Yield

-

CAI Company Profile


Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,769

IPO Date

Jun 18, 2025

Website

CAI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 25Jun 25
Pharma Research And Development Services$9.25M$18.47M

Fiscal year ends in Dec 20 | Currency in USD

CAI Financial Summary


Dec 20Dec 19Dec 18
Revenue$294.01M$416.54M$432.10M
Operating Income$139.09M$130.28M$148.78M
Net Income$27.73M$31.01M$78.60M
EBITDA$201.75M$228.29M$283.31M
Basic EPS$1.55$1.72$3.97
Diluted EPS$1.55$1.72$3.97

Fiscal year ends in Dec 20 | Currency in USD

Latest Earnings Call Transcripts


Q3 25Nov 05, 25 | 4:30 PM

Peer Comparison


TickerCompany
JAZZJazz Pharmaceuticals plc
RYTMRhythm Pharmaceuticals, Inc.
RNAAvidity Biosciences, Inc.
ABVXAbivax S.A.
CORTCorcept Therapeutics Incorporated
MRNAModerna, Inc.
MRUSMerus N.V.
HALOHalozyme Therapeutics, Inc.
CYTKCytokinetics, Incorporated
MDGLMadrigal Pharmaceuticals, Inc.